As Malaysia’s daily Covid-19 infections per million people, on a seven-day rolling basis, have exceeded that of India, it comes as a relief that more vaccines are beings secured for Malaysians.
According to CNBC, latest statistics showed that Malaysia reported 205.1 cases per million people on a seven-day rolling basis, on Tuesday, compared with India’s 150.4 cases.
That is a scary thought.
Pharmaniaga Bhd has recently announced that it is confident the company will be able to supply 8.6 million doses of the Sinovac Covid-19 vaccine by the end of June.
Pharmaniaga group managing director Datuk Zulkarnain Md Eusope said 3.6 million doses would be available in May.
“The other five million will be available in June,” he said adding that the company was on track to meet their contractual obligation to the Federal Government.
It was earlier reported that Pharmaniaga promised a delivery schedule of “fill and finish” production of the Sinovac Covid-19 vaccine.
Earlier, National Covid-19 Immunisation Programme (NIP) coordinating minister Khairy Jamaluddin was reported saying that the “fill and finish” production of the Sinovac Covid-19 vaccines by Pharmaniaga Life Science Sdn Bhd at its plant in Puchong was of equal quality to the ones manufactured at the Sinovac Biotech Ltd’s factory in Beijing.
The vaccines were said to have gone through stringent processes and procedures as required by the National Pharmaceutical Regulatory Agency (NPRA) before they are distributed to vaccination centres (PPV) around the country.